CD33 and acute myeloid leukemia: Currently, there are several clinical trials testing CAR-T cells in AML, mostly targeting CLL1, CD123, and CD33, that are all myeloid antigens overexpressed in leukemic blasts but also in their normal stem cell counterpart; however, various other myeloid antigens (e.g., CD64, CD13, CD93, and CD38) as well as repurposed lymphoid antigens (e.g., CD19, CD7, and CD70) are under investigation.